Home Capital Results

iX Biopharma reverses from losses to net profit of $3.7 mil in 1HFY2022 from out-licensing of Wafermine

Felicia Tan
Felicia Tan2/11/2022 01:30 PM GMT+08  • 2 min read
iX Biopharma reverses from losses to net profit of $3.7 mil in 1HFY2022 from out-licensing of Wafermine
Eddy Lee, chairman and CEO of iX Biopharma, called the positive results a "significant inflection" for the business.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

iX Biopharma has reported net profit of $3.7 million for the 1HFY2022 ended December, reversing from its loss of $2.8 million in the same period the year before.

1HFY2022 earnings per share (EPS) stood at 0.49 cents from the loss per share of 0.41 cents in the 1HFY2020.

Revenue surged nearly 16 times to $13.2 million in the 1HFY2022 from $830,000 due to the income from the out-licensing of Wafermine to Seelos Therapeutics in November 2021.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now